论文部分内容阅读
目的 TheefficacyofEGFRtyrosinekinaseinhibitors(TKIs)variesamongdifferentEGFRmutations.Here,wedirectlycomparedtheefficacyoffirst-lineTKIstochemotherapyfornon-smallcelllungcancer(NSCLC)patientswiththeL858Rmutation.方法 WeidentifiedandreviewedtheclinicaldataofpatientswhowerediagnosedwithNSCLCattheShanghaiChestHospitalbetweenbetweenJanuary2011andDecember2013.